Jacob Borrajo is the Co-founder and CEO at Amber Bio. Previously, he served as the co-founder of Coral Genomics and Scribio, and has worked on VLP-based delivery of CRISPR-Cas systems and novel RNA measurement technologies. His greatest interests are i) to build technologies to measure new properties of biological systems ii) to apply synthetic biology approaches to create solutions to health-related problems and iii) to develop hardware-free technology by replacing hardware-intensive processes with simplified biological analogs.

Borrajo holds PhD in Biological Engineering from Massachusetts Institute of Technology, and he completed BS in Chemical and Biomolecular Engineering from UCLA.